Abstract: The present invention relates to a nutritional composition comprising non-denatured lactoferrin for use in preventing or treating allergy, allergic rhinitis, asthma, urticaria, atopic eczema, allergic conjunctivitis, atopic dermatitis or atopic diseases in an infant or a toddler.

Abstract: The invention pertains to non-dairy proteins and nutritional compositions comprising non-dairy protein suitable for infant nutrition and a method of preparing a nutritional composition for infants or young children comprising non-dairy protein.

Abstract: The present invention relates to a nutritional composition for infants, for use in reducing the risk of developing non-alcoholic fatty liver disease in infants at risk of developing non-alcoholic fatty liver disease.

Abstract: The present invention relates to formulae for infants born to a mother that is overweight or obese at the time of conception of the infant for improving the postnatal growth trajectory or body development.

Abstract: The present invention relates to formulae for infants born via Caesarean section for improving the postnatal growth trajectory or body development.

Abstract: The invention provides a computer-implemented method of detecting a liquid level inside a container, the method comprising the steps of: capturing, by a camera of a portable device, a first image of the container; providing the first image to an input layer of a convolutional neural network, CNN; obtaining, from a final layer of the CNN, the liquid level inside the container in the first image; and storing the obtained liquid level, wherein the CNN is configured to identify features of a plurality of volume indicators of the container in the first image and determine the liquid level in the container in the first image based on the identified features.

Abstract: An infant formula for preventing gastro-esophageal reflux is disclosed comprising whey protein and/or casein, a galactomannan thickener, and a fermented milk-derived product.

Abstract: The invention provides for an enteral nutritional composition comprising (a) a lipid fraction, (b) a digestible carbohydrate fraction and (c) a protein fraction, wherein the lipid fraction comprises therapeutically effective amounts of (i) DHA and optionally EPA, and (ii) medium-chain triglycerides, preferably at least 2 wt % C8 and C10 medium-chain triglycerides based on weight of the fatty acids; and wherein the composition has a ketogenic weight ratio between 1.4:1 and 3:1, for use in the treatment of traumatic brain injury (TBI).

Abstract: The invention relates to compositions comprising EPA, MA and leucine for prevention and/or treatment of a disease or condition involving muscle decline or for improving muscle function.

Abstract: The invention thus pertains to the use of a composition comprising: (a) uridine or uridine phosphate; and (b) docosahexaenoic acid and/or eicosapentaenoic acid, for improving memory and/or the treatment or prevention of impaired memory function, in a subject with a mini-mental state examination of 24-26, wherein said composition is enterally administered to the subject. In the MMSE test, any score of 27 or higher (out of 30) is effectively normal. In the patients with dementia, 20-26 indicates mild dementia, 10-19 moderate dementia, and below 10 severe dementia. It was the present inventors' belief that within the group of 20-26, the memory impairment in the sub-group of 24-26 may even be reversible, as the pathological pathways have just started to develop. In this group of subjects the pathological pathways have just started to develop. Clinical studies show excellent results for this subgroup.

Abstract: The present invention relates to the field of processing food. Particularly, the present invention relates to a method of preparing a fruit-containing product using high pressure pasteurization. The fruit-containing product obtained by the method of the invention is microbiologically safe and can be stored at ambient temperatures. The fruit-containing product according to the invention can be used to feed babies and infants during mixed diet introduction.

Abstract: The present invention concerns a process for manufacturing an infant formula product comprising: (a1) providing an aqueous mixture having a protein component and a carbohydrate component, (a2) subjecting the aqueous mixture to a heat treatment step, (a3) subjecting the heat-treated, aqueous mixture to a fermentation step using a bacterial fermentation culture; (b) mixing the fermented, aqueous mixture with a lipid component; (c) subjecting the fermented, aqueous mixture comprising the lipid component, the carbohydrate component and the heat-treated protein component to a homogenization and emulsification step to obtain a homogenized oil-in-water emulsion having a total solids content in the range of 45-73 wt %; (d) conveying the homogenized emulsion into an extruder, independently adding digestible carbohydrates and optionally dietary fibres to the extruder and extruding the contents of the extruder to obtain an extruded material; (e) preparing an infant formula product from the extruded material.

Abstract: The present invention relates to an infant formula comprising non digestible oligosaccharides for reducing or preventing proteolytic fermentation in the gastro-intestinal tract.

Abstract: The present invention concerns a process for manufacturing an infant formula product comprising lipid globules having a volume-weighted mode diameter of at least 1.

Abstract: The invention thus pertains to the use of a composition comprising: (a) uridine or uridine phosphate; and (b) docosahexaenoic acid and/or eicosapentaenoic acid, for improving memory and/or the treatment or prevention of impaired memory function, in a subject with a mini-mental state examination of 24-26, wherein said composition is enterally administered to the subject. In the MMSE test, any score of 27 or higher (out of 30) is effectively normal. In the patients with dementia, 20-26 indicates mild dementia, 10-19 moderate dementia, and below 10 severe dementia. It was the present inventors' belief that within the group of 20-26, the memory impairment in the sub-group of 24-26 may even be reversible, as the pathological pathways have just started to develop. In this group of subjects the pathological pathways have just started to develop. Clinical studies show excellent results for this subgroup.

Abstract: The present invention concerns a process for manufacturing an infant formula product comprising: (a) subjecting an aqueous mixture having a protein component and a carbohydrate component to a heat treatment step; (b) mixing the aqueous mixture with a lipid component; (c) subjecting the aqueous mixture comprising the lipid component, the carbohydrate component and the heat-treated protein component to a homogenization and emulsification step to obtain a homogenized oil-in-water emulsion having a total solids content in the range of 45-80 wt %; (d) conveying the homogenized emulsion into an extruder, independently adding digestible carbohydrates and optionally dietary fibres to the extruder and extruding the contents of the extruder wherein a gas is injected into the extruder, to obtain an extruded aerated material (e) preparing an infant formula product from the extruded aerated material.

Abstract: The invention pertains to the use of a probiotic and a beta-lactoglobulin-derived peptide in the manufacture of a product for use in inducing oral tolerance, and/or treatment, prevention or reducing the risk of allergy in a subject, in particular cow's milk protein allergy.

Abstract: The present invention relates to formulae for infants comprising large lipid globules and/or lipid globules with a coating of phospholipids for rendering the growth trajectory or body development during the first year of life more similar to that observed for human milk fed infants.

Abstract: The invention relates to the use of beta1,3?-galactosyllactose for improving the gut barrier function. This can in particular be administered to subjects at risk for increased gut barrier permeability, preferably infants and young children.

Abstract: The present invention relates to a combination of Vitamin A and non-digestible oligosaccharides for use in treating and/or preventing allergy.